Evolving Role of Radiation Therapy for Hematologic Malignancies

Hematology/Oncology Clinics of North America

Volumn 20, Issue 2, 2006, Pages 471-503

  Lee, Chung K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINBLASTINE; VINCRISTINE;

CANCER INCIDENCE; CANCER STAGING; CORONARY ARTERY DISEASE; ENZYME DEFECT; GASTROINTESTINAL DISEASE; HEMATOLOGIC MALIGNANCY; HISTOLOGY; HODGKIN DISEASE; HUMAN; LEUKEMIA; LUNG FIBROSIS; LUNG PARENCHYMA; NEOPLASM; NONHODGKIN LYMPHOMA; PERICARDITIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; SPINAL CORD DISEASE; STOMACH LYMPHOMA; THYROID DISEASE; UNITED STATES; VALVULAR HEART DISEASE; WALDEYER RING; XEROSTOMIA;

HEMATOLOGIC NEOPLASMS; HODGKIN DISEASE; HUMANS; LEUKEMIA; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; PLASMACYTOMA;

EID: 33646778504     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2006.01.020     Document Type: Review

References (160)

1. Gilber R. Radiotherapy in Hodgkin's disease (malignant granulomatosis): anatomic and clinical foundations; governing principles; results. Am J Roentgenol Radium Ther Nucl Med 41 (1939) 198-241
2. Peters M.V. A study in survivals in Hodgkin's disease treated radiologically. AJR Am J Roentgenol 63 (1950) 299-311
3. Easson E., and Russell M. The cure of Hodgkin's disease. BMJ 1 (1963) 1704-1707
4. Rosenberg S.A., Kaplan H.S., Hoppe R.T., et al. The Stanford randomized trials of the treatment of Hodgkin's disease 1967-1980. In: Rosenberg S.A., and Kaplan H.S. (Eds). Malignant lymphomas: etiology, immunology, pathology, treatment (1982), Academic Press, New York 513-522
5. Gospodarowicz M.K., Sutcliffe S.B., Clark R.M., et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone. Int J Radiat Oncol Biol Phys 22 (1922) 859-865
6. Lee C.K.K., Aeppli D.M., Bloomfield C.D., et al. Curative radiotherapy for laparotomy-staged IA, IIA, IIIA Hodgkin's disease. An evaluation of the gains achieved with radical radiotherapy. Int J Radiat Oncol Biol Phys 19 (1990) 547-549
7. Castellino R.A., Blank N., Hoppe R.T., et al. Hodgkin's disease: contributions of chest CT in the initial staging evaluation. Radiology 160 (1986) 603-605
8. Rostock R.A., Siegelman S.S., Lenhard R.E., et al. Thoracic CT scanning for mediastinal Hodgkin's disease. Results and therapeutic implications. Int J Radiat Oncol Biol Phys 9 (1983) 1451-1457
9. Lee C.K., Bloomfield C.D., Goldman A.J., et al. Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy. Cancer 46 (1980) 2403-2409
10. Mauch P., Tarbell N., Weinstein H., et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease. Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 6 (1998) 1576-1583
11. Leibenhaut M., Hoppe R., Efron B., et al. Prognostic indications of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. J Clin Oncol 7 (1989) 81-91
12. Mauch P., Larson D., Osteen R., et al. Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol 8 (1990) 257-265
13. Brada M., Easton D., Horwich A., et al. Clinical presentation as a predictor of laparotomy findings in supradiaphragmatic stage I and II Hodgkin's disease. Radiother Oncol 5 (1986) 15-22
14. Tubiana M., Henry-Amar M., Carde P., et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 73 (1989) 47-56
15. Jones E., and Mauch P. Limited radiation therapy for selected patients with pathological stages IA and IIA Hodgkin's disease. Semin Radiat Oncol 6 (1996) 162-171
16. Specht L., and Nissen N.I. Hodgkin's disease stages I and II with infradiaphragmatic presentation: a rare and prognostically unfavorable combination. Eur J Haematol 40 (1988) 396-402
17. Lee C.K.K., Aeppli D.M., Bloomfield C.D., et al. Curative radiotherapy for laparotomy-staged IA, IIA, IIIA Hodgkin's disease. An evaluation of the gains achieved with radical radiotherapy. Int J Radiat Oncol Biol Phys 19 (1990) 547-549
18. Lee C.K.K., Bloomfield C.D., Golman A., et al. Liver irradiation in stage IIIA Hodgkin's disease patients with splenic involvement. Am J Clin Oncol 7 (1984) 149-157
19. Hoppe R.T., Coleman C.N., Cox R.S., et al. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 59 (1982) 455-465
20. Straus D., Yahalom J., Gaynor J., et al. Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate-stage Hodgkin's disease. Cancer 69 (1992) 1052-1060
21. Specht L., Gray R.G., Clarke M.J., et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 16 (1998) 830-843
22. Stein R.S., Hilborn R.M., Flesner J.M., et al. Anatomical substages of stage III Hodgkin's disease: implications for staging, therapy, and experimental design. Cancer 42 (1978) 429-436
23. Mauch P., Goffman T., Rosenthal D.S., et al. Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone. J Clin Oncol 3 (1985) 1166-1173
24. Marcus K.C., Kalish L.A., Coleman C.N., et al. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy. J Clin Oncol 12 (1994) 2567-2572
25. Longo D.L., Young R.C., Wesley M., et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4 (1986) 1295-1306
26. Mauch P.M., Kalish L.A., Marcus K.C., et al. Long-term survival in Hodgkin's disease: relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1 (1995) 33-42
27. Tucker M.A., Coleman C.N., Cox R.S., et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318 (1988) 76-81
28. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's disease. Ann Oncol 3 (1992) 117-128
29. American Joint Committee on Cancer. AJCC cancer staging handbook (1998), Lippincott-Raven, Philadephia 259
30. Carbone P.P., Kaplan H.S., Musshoff K., et al. Report of the committee on Hodgkin's staging classification. Cancer Res 31 (1971) 1860
31. Lister T., Crowther D., Sutcliffe S., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7 (1989) 1630-1636
32. Specht L.K., and Hasenclever D. Prognostic factors of Hodgkin's disease. In: Mauch P.M., Armitage J.O., Diehl V., et al. (Eds). Hodgkin's disease (1999), Lippincott Williams & Wilkins, Philadelphia
33. Somers R., Tubiana M., Henry-Amar M., and EORTC Lymphoma Cooperative Group. Studies in clinical stage I-II Hodgkin's disease 1963-1987. Recent Results Cancer Res 117 (1989) 175-181
34. Loeffler M., Pfreundschuh M., and Rühl U. Risk factor adapted treatment of Hodgkin's lymphoma: strategies and perspectives. Recent Results Cancer Res 117 (1989) 142-162
35. Noordijk E.M., Carde P., Hagenbeek A., et al. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease. Six-year results of the EORTC-GPMC controlled clinical trials H7-VF, H7-F and H7-U [abstract 177]. Int J Radiat Oncol Biol Phys 39 (1997) 173
36. Lee C.K., Aeppli D.M., Bloomfield C.D., et al. Hodgkin's disease: A reassessment of prognostic factors following modification of radiotherapy. Int J Radiation Oncol Biol Phys 13 (1987) 983
37. Farah R., Ultmann J., Griem M., et al. Extended mantle radiation therapy for pathologic stage I and II Hodgkin's disease. J Clin Oncol 6 (1988) 1047
38. Yelle L., Bergsagel D., Basco V., et al. Combined modality therapy of Hodgkin's disease: 10 year results of National Cancer Institute of Canada Trials Group multicenter clinical trail. J Clin Oncol 9 (1998) 1983
39. Grozea P.N., DePersio E.J., Coltman Jr. C.A., et al. Chemotherapy Alone Versus Combined Modality Therapy for Stage III Hodgkin's: A Five-Year Follow-up of a Southwest Oncology Group Study (SWOG-7518). In: Cavalli F., Bonnadonna G., and Rozencweig M. (Eds). Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances (1985), Martinus Nijhoff Publishing 345-351
40. Ganesan T.S., Wrigley P.F., Murray P.A., et al. Radiotherapy for stage I Hodgkin's disease: 20 years' experience at St. Bartholomew's Hospital. Br J Cancer 62 (1990) 314
41. Rock D.B., Schultz C.J., Murray R.J., et al. Continuous split course irradiation for stage I and II Hodgkin's disease: 20 year experience at the Medical College of Wisconsin. Radiother Oncol 30 (1994) 222
42. Hartsell W.F., Farah R., Murthy A., et al. Is pelvic irradiation necessary in stage III1A Hodgkin's disease. Int J Radiat Oncol Biol Phys 19 (1990) 715
43. Mauch P.M., Kalish L.A., Marcus K.C., et al. Long-term survival in Hodgkin's disease: relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1 (1995) 33-42
44. Tucker M.A., Coleman C.N., Cox R.S., et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318 (1998) 76-81
45. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's disease. Ann Oncol 3 (1992) 117-128
46. Aleman B.M.P., van den Belt-Dusebout A.W., Klokman W.J., et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21 (2003) 3431-3439
47. Linch D.C., Gosden R.G., Tulandi T., et al. Hodgkin's lymphoma: choice of therapy and late complications. Hematology (Am Soc Hematol Educ Program) 5 (2000) 205-221
48. Dores G.M., Metayer C., Curtis R.E., et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 20 (2002) 3483-3494
49. Ng A.K., Bernardo M.V.P., Weller E., et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100 (2002) 1989-1996
50. Press O.W., LeBland M., Lichter A.S., et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for Stage IA to IIA Hodgkin's disease. J Clin Oncol 19 (2001) 4238-4244
51. Horning S.J., Hoppe R.T., Mason J., et al. Stanford-Kaiser permanent G1 study for clinical stage I to IIA Hodgkin's disease: Subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 15 (1997) 1736-1744
52. Noordijk E.M., Thomas J., Ferme C., et al. First results of the EORTC-GELA H9-F randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL) [abstract 6505]. Program and abstracts of the 41st Annual Meeting of the American Society of Clinical Oncology: May 13-17, 2005; Orlando, Florida
53. Diehl V., Brilliant C., Engert A., et al. HD10: investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma: interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG) [abstract 6506]. J Clin Oncol 23 (2005) 561
54. Brusamolino E., Luhghi F., Orlandi E., et al. Treatment of early stage HD with 4 cycles of ABVD followed by adjuvant radiotherapy: Analysis of efficacy and long term toxicity. Haemtologica 85 (2000) 1032-1039
55. Angelopoulou M.K., Vassilakopoulos T.P., Siakantari M.P., et al. EBVD combination chemotherapy plus low dose involved field radiation is highly effective treatment modality for early stage Hodgkin's disease. Leukemia and Lymphoma 37 (2000) 131-143
56. Santoro A., Bonfante V., Viviani S., et al. Subtotal nodal versus involved field irradiation after 4 cycles of ABVD in early stage Hodgkin's disease. Proceedings of American Society of Clinical Oncology 15 (1996) 415
57. Klasa R., Connors J.M., Hoskins P., et al. Early stage Hodgkin's disease: Impact of brief chemotherapy together with radiotherapy without staging laparotomy. Proceedings of American Society of Clinical Oncology 13 (1994) 372
58. Liao Z., Ha C.S., Fuller L.M., et al. Subdiaphragmatic stage I and II Hodgkin's disease: long-term follow-up and prognostic factors. Int J Radiat Oncol Biol Phys 41 (1998) 1047-1056
59. Biti G.A., Climino G., Cartoni C., et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-II A Hodgkin's disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 10 (1992) 378-382
60. Hanks G.E., Kinzie J.J., White R.L., et al. Patterns of care outcome studies: results of the national practice in Hodgkin's disease. Cancer 51 (1983) 569-573
61. Wolf J., Tesch H., Parsa-Parsi R., et al. Current clinical trials for the treatment of adult Hodgkin's disease: common strategies and perspectives. Ann Oncol 9 (1998) S79-S82
62. Santoro A., Bonfante S., Viviani M., et al. Four cycles of ABVD followed by involved field irradiation (IF-RT) is the treatment of choice for early stage Hodgkin's disease (HD): 5-year results of a randomized trial [abstract 1185]. Eur J Cancer 33 Suppl 8 (1997) 262
63. Horning S.J., Hoppe R.T., Breslin S., et al. Brief chemotherapy (CT) (Stanford V) and involved field radiotherapy (RT) are highly effective for advanced Hodgkin's disease [abstract]. Proc Am Soc Clin Oncol 17 (1998) 16
64. Horning S.J., Williams J., Bartlett N.L., et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 18 (2000) 972-980
65. Hudson M.M., Poquette C.A., Lee J., et al. Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncolo 15 (1998) 3592-3600
66. Palos B., Kaplan H.S., and Karzmark C.J. The use of thin lung shields to deliver limited whole-ling irradiation during mantle-field treatment of Hodgkin's disease. Radiology 101 (1971) 441-442
67. Lee C.K.K. Hodgkin's Disease. In: Levitt S.H., Khan F.M., Perez C.A., et al. (Eds). Technological Basis of Radiation Therapy Clinical Applications. 3rd ed (1998), Lippincott, Williams, & Wilkins, Philadelphia 519-542
68. Pavlovsky S., Maschio M., Santarelli M.T., et al. Randomized trail of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 80 (1988) 1466-1473
69. Cosset J.M., Henry-Amar M., and Meerwaldt J.H. Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol 2 (1991) 77-82
70. Hancock S.L., Tucker M.A., and Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270 (1993) 1949-1955
71. Hancock S.L., and Hoppe R.T. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 6 (1996) 225-242
72. Lee C.K.K., Aeppli D., and Niergengarten M.E. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 1 (2000) 169-179
73. Lee C.K.K., Bloomfield C.D., Goldman A., et al. Liver irradiation in stage IIIA Hodgkin's disease patients with splenic involvement. Am J Clin Oncol 7 (1984) 149-157
74. Coia L.R., and Hanks G.E. Complications from large field intermediate dose infradiaphragmatic radiation: an analysis of the Patterns of Care Outcomes Studies for Hodgkin's disease and seminoma. Int J Radiat Oncol Biol Phys 15 (1988) 29-35
75. Miller R.W., Van de Geijn J., Raubitscheck A.A., et al. Dosimetric considerations treating mediastinal disease with mantle fields: characterization of the dose under mantle blocks. Int Radiat Oncol Biol Phys 32 (1995) 1083-1095
76. Horning S.J., Hoppe R.T., Hancock S.L., et al. Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 6 (1988) 1822-1831
77. Hancock S.L., Tucker M.A., and Hoppe R.T. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85 (1993) 25-31
78. Birdwell S.H., Hancock S.L., Varghese A., et al. Gastrointestinal cancer after treatment of Hodgkin's disease. Int J Radiat Oncol Biol Phys 37 (1995) 67-73
79. van Leeuwen F.D., Klokman W.J., Stovall M., et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 87 (1995) 1530-1537
80. Mauch P., Kalish L.A., Marcus K.C., et al. Long-term survival in Hodgkin's disease: relative impact of mortality, second tumors infection, and cardiovascular disease. Cancer J Sci Am 1 (1995) 33-42
81. Schonfeld S.J., Gilbert E.S., Dores G.M., et al. Acute leukemia (AL) following Hodgkin's lymphoma (HL): a population-based study of over 38,000 patients. J Clin Oncol 23 (2005) 562s
82. Rappaport H. Tumor of the hematopoietic system. Atlas of tumor pathology, sect 3, fasc 8 (1966), Armed Forces Institute of Pathology, Washington (DC)
83. Stansfeld A.G., Diebold J., Noel H., et al. Updated Kiel classification for lymphomas. Lancet 1 (1988) 292-293
84. Non-Hodgkin's Lymphoma Pathologic Classification Project. Summary and description of a working formulation for clinical usage. Cancer 49 (1982) 2112
85. Harris N., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (1984) 1361
86. Shipp M.A., Harrington D.P., Anderson J.R., et al. A predictive model for aggressive NHL: International NHL Prognostic Factors project. N Engl J Med 329 (1993) 987
87. Shipp M.A. Prognostic factors in aggressive NHL: who has "high risk" disease?. Blood 83 (1994) 1165
88. Mauch P., Leonard R., Skarin A., et al. Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas. J Clin Oncol 3 (1985) 1301
89. MacManus M.P., and Hoppe R.T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14 (1996) 1282
90. Vaughan H.B., Vaughan H.G., MacLennan K.A., et al. Clinical stage I non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 60 (1994) 1088
91. Suttcliffe S.B., Gospadarowicz M.K., Bush R.S., et al. Role of radiation therapy in localized non-Hodgkin's disease lymphoma. Radiother Oncol 4 (1985) 211
92. Nissen N.I., Ersboll J., Hansen H.S., et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer 42 (1983) 1
93. Monfardini S., Banfi A., Bonadonna G., et al. Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 6 (1980) 125
94. Carde P., Burgers J.M.W., Glabbeke M., et al. Combined radiotherapy-chemotherapy for early stage non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial. Radiother Oncol 2 (1984) 301
95. Yahalom J., Varsos G., Fuks Z., et al. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 71 (1993) 2342
96. Kelsey S.M., Newland A.C., Vaughn H.G., et al. A BNLI randomized trial of chlorambucil plus radiotherapy versus radiotherapy alone in low-grade, localized non-Hodgkin's lymphoma. Radiat Oncol 11 (1994) 19
97. Payrani S.B., Hoppe R.T., Cox R.S., et al. The role of radiation therapy in the management of stage III follicular lymphomas. J Clin Oncol 2 (1984) 841
98. Jacobs J.P., Murray J.K., Schultz C.J., et al. Central lymphatic irradiation for stage III nodular malignant lymphoma: long-term results. J Clin Oncol 11 (1993) 233
99. Mendenhall N.P., and Lynch J.W. The low-grade lymphomas. Semin Radiat Oncol 5 (1995) 267
100. Carabell S.C., Chaffy J.T., Rosenthal D.S., et al. Results of total body irradiation in the treatment of advanced non-Hodgkin's lymphomas. Cancer 43 (1979) 994
101. Johnson R.E. Total body irradiation (TBI) as primary therapy for advanced lymphosarcoma. Cancer 35 (1975) 242
102. Qasim M. Blood and bone marrow response following total body irradiation in patients with lymphosarcoma. Eur J Cancer 13 (1987) 483
103. Arthur K. Follicular lymphoma-a review of 58 cases. Clin Radiol 19 (1968) 347-350
104. Bush R.S., Gospadarowicz M., Sturgeon J., et al. Radiation therapy of localized non-Hodgkin's lymphoma. Cancer Treat Rep 61 (1997) 1129
105. Ha C.S., Tucker S.L., Lee M.-S., et al. The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21). Int J Radiat Oncol Biol Phys 49 (2002) 727-732
106. Cox J.D. Cure and follicular lymphoma. Int J Radiat Oncol Biol Phys 38 (1997) 1-2
107. Hallahan D.E., Farah R., Vokes E.E., et al. The patterns of failure in patients with pathological stag I and II diffuse histiocytic lymphoma treated with radiation therapy alone. Int J Radiat Oncol Biol Phys 17 (1989) 767
108. Levitt S.H., Lee C.K.K., Bloomfield C.D., et al. The role of radiation therapy in the treatment of early state large cell lymphoma. Hematol Oncol 3 (1985) 33-37
109. McLaughlin P., Fuller L., Velasquez W.S., et al. Stage I-II follicular lymphoma: treatment results for 76 patients. Cancer 58 (1986) 1596
110. Seymour J.F., McLaughlin P., Fuller L.M., et al. High rate of prolonged remission following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol 7 (1996) 157
111. Glick J., Kim K., Earle J., et al. An ECOG randomized phase III trial of CHOP vs. CHOP + radiotherapy for intermediate grade early stage non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 14 (1995) 391
112. Miller T., Dahlberg S., Cassady J., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 (1998) 21
113. Kirklove C., and Timothy A.R. Radiotherapy as salvage treatment in patients with Hodgkin's disease or non-Hodgkin's lymphoma relapsing after initial chemotherapy. Hematol Oncol 9 (1991) 163
114. Gale R.P., Butturini A., and Bortin M.M. What does total body irradiation do in bone marrow transplants for leukemia?. Int J Radiat Oncol Biol Phys 20 (1991) 631
115. d'Amore F., Christensen B.E., Brinker H., et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin's lymphomas. Eur J Cancer 27 (1991) 1201
116. Otter R., Gerrits W.B., Sandt M.M., et al. Primary extranodal and nodal non-Hodgkin's lymphoma: a survey of population-based registry. Eur J Cancer 25 (1989) 1203-1210
117. Gospadarowicz M.K., and Sutcliffe S.B. The extranodal lymphomas. Semin Radiat Oncol 5 (1995) 281
118. Roggero E., Zucca E., Pinotti G., et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 122 (1985) 767
119. Montalban C., Boixeda D., and Bellas C. Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphomas. Ann Intern Med 124 (1996) 275
120. Schechter N., Portlock C., Filippa D., et al. The treatment of MALT lymphoma of the stomach with radiation alone. J Clin Oncol 16 (1998) 1916
121. Maor M.H., Velasquez W.S., Fuller L.M., et al. Stomach conservation in stages IE and IIE gastric non-Hodgkin's lymphoma. J Clin Oncol 8 (1990) 266
122. Koch P., Grothaus-Pinke B., Hiddemann W., et al. Primary lymphoma of the stomach: three-year results of a prospective multicenter study: The German Multicenter Study Group on GI-NHL. Ann Oncol 8 Suppl 1 (1997) 85
123. Taal B.G., and Burgers J.M. Primary non-Hogkin's lymphoma of the stomach: endoscopic diagnosis and the role of surgery. Scand J Gastroenterol 188 (1991) 33
124. Liang R., Ng R.P., Todd D., et al. Management of stage I-II diffuse aggressive non-Hodgkin's lymphoma of the Waldeyer's ring: combined modality therapy versus radiotherapy alone. Hematol Oncol 5 (1987) 223
125. Ossenkoppele G.J., Mol J.J., Snow G.B., et al. Radiotherapy versus radiotherapy plus chemotherapy in stages I and II non-Hodgkin's lymphoma of the upper digestive and respiratory tract. Cancer 60 (1987) 1505
126. Aviles A., Delgado S., Ruiz H., et al. Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined modality therapy. Eur J Cancer 32 (1996) 19
127. Logsdon M., Ha C., Kavadi V., et al. Lymphoma of the nasal cavity and paranasal sinuses. Cancer 80 (1997) 477
128. Jaffe E.S., Chan J., Su I.J., et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas: definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 20 (1996) 103
129. Weiss L.M., Arber D.A., and Strickler J.G. Nasal T-cell lymphoma. Ann Oncol 1 (1994) 139
130. Aviles A., Rodriguez L., Guzman R., et al. Angiocentric T-cell lymphoma of the nose, paranasal sinuses and hard palate. Hematol Oncol 10 (1992) 141
131. Pariente D., Anaya J.M., Combe B., et al. Non-Hodgkin's lymphoma associated with primary Sjögren's syndrome. Eur J Med 1 (1992) 337
132. Bessell E.M., Henk J.M., Wright J.E., et al. Orbital and conjunctival lymphoma treatment and prognosis. Radiother Oncol 13 (1998) 237
133. Fitzpatrick P.J., and Macko S.M. Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys 10 (1984) 333
134. Zimmerman H.M. Malignant lymphomas of the central nervous system. Acta Neuropathol (Berl) 6 Suppl (1975) 69
135. Eby N.L., Grufferman S., Flannelly C.M., et al. Increasing incidence of primary brain lymphoma in the US. Cancer 62 (1988) 2461
136. Jellinger K.A., and Paulus W. Primary central nervous system lymphomas-new pathological developments. J Neurooncol 24 (1995) 33
137. Miller D.C., Hochberg F.H., Harris N.L., et al. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma: the Massachusetts General Hospital experience 1958-1989. Cancer 74 (1994) 1383
138. Tomlinson F.H., Kurtin P.J., Suman V.J., et al. Primary intracerebral lymphoma: a clinicopathological study. J Neurosurg 82 (1995) 558
139. DeAngelis L.M. Current management of primary central nervous system lymphoma. Oncology 9 (1995) 63
140. Nelson D.F., Martz K.L., Bonner H., et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23 (1992) 9
141. DeAngelis L.M., Yahalom J., Thayer M.T., et al. Combined modality therapy for primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9 (1991) 1580
142. Leibel S.A., and Sheline G.E. Radiation therapy for neoplasms of the brain. J Neurosurg 66 (1987) 1
143. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361-1392
144. Lo T.C., Salzman F.A., Moschella S.L., et al. Whole body surface electron irradiation in the treatment of mycosis fungoides. Radiology 130 (1979) 453-457
145. Pendlebury S., el Awadi M., Ashley S., et al. Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiother Oncol 36 (1995) 167-171
146. Kim Y.H., and Hoppe R.T. Mycosis fungoides and the Sezary syndrome. Semin Oncol 26 (1999) 276-289
147. Diamandidou E., Cohen P.R., and Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood 88 (1996) 2385-2409
148. Hoppe R.T. The management of mycosis fungoides at Stanford-standard and innovative treatment programmes. Leukemia 5 (1991) 46-48
149. Kaye F.J., Bunn P.A., Steinberg S.M., et al. A randomized trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 (1989) 1784-1790
150. Cotter G.W., Baglan R.J., Wasserman T.H., et al. Palliative radiation treatment of cutaneous mycosis fungoides-a dose response. Int J Radiat Oncol Biol Phys 9 (1983) 1477-1480
151. Herrmann J.J., Roenigk Jr. H.H., Hurria A., et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. Acad Dermatol 33 (1995) 234-242
152. Watson A. Photochemotherapy for mycosis fungoides: current status. Australas J Dermatol 38 (1997) 9-11
153. Mill W.B., and Griffith R. The role of radiation therapy in the management of plasma cell tumors. Cancer 45 (1980) 647
154. Fitzpatrick P.J., and Rider W.D. Half body radiotherapy. Int J Radiat Oncol Biol Phys 1 (1976) 197
155. Mill W.B. Radiation therapy in multiple myeloma. Radiology 115 (1975) 175
156. Mill W.B., and Wasserman T.H. Multiple myeloma and plasmacytomas. In: Perez C.A., and Brady L.W. (Eds). Principles and practice of radiation oncology (1987), JB Lippincott, Philadelphia 1086
157. Frassica D.A., Frassica F.J., Schray M.F., et al. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys 16 (1989) 43
158. Dimopoulos M.A., Moulopoulos A., Delasalle K., et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Hematol Oncol Clin North Am 6 (1992) 359
159. Liebross R.H., Ha C.S., Cox J.D., et al. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol 52 (1999) 245-249
160. Knowling M.A., Harwood A.R., and Bergsagel D.E. Comparison of extra medullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1 (1983) 255